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Abstract. Chemotherapy for suppressing tumor growth and 
metastasis tends to induce various effects on other organs. 
Using AZD7762, an inhibitor of checkpoint kinase (Chk) 1 
and 2, the present study examined its effect on mammary 
tumor cells in addition to bone cells (osteoclasts, osteoblasts 
and osteocytes), using monolayer cell cultures and three-
dimensional (3D) cell spheroids. The results revealed that 
AZD7762 blocked the proliferation of 4T1.2 mammary 
tumor cells and suppressed the development of RAW264.7 
pre-osteoclast cells by downregulating nuclear factor of 
activated T cells cytoplasmic 1. AZD7762 also promoted the 
mineralization of MC3T3 osteoblast-like cells and 3D bio-
printed bone constructs of MLO-A5 osteocyte spheroids. 
While a Chk1 inhibitor, PD407824, suppressed the prolifera-
tion of tumor cells and the differentiation of pre-osteoclasts, 
its effect on gene expression in osteoblasts was markedly 
different compared with AZD7762. Western blotting indi-
cated that the stimulating effect of AZD7762 on osteoblast 
development was associated with the inhibition of Chk2 and 
the downregulation of cellular tumor antigen p53. The results 
of the present study indicated that in addition to acting as 
a tumor suppressor, AZD7762 may prevent bone loss by 
inhibiting osteoclastogenesis and stimulating osteoblast 
mineralization.
Introduction
Checkpoint kinases (Chks) are serine/threonine kinases that 
serve a critical role in cell cycle control, DNA damage responses 
and cell survival (1). Chks have two subtypes, Chk1 and Chk2, 
and they are highly conserved from yeast to humans (2). The 
upregulation of Chks induces cell cycle arrest, while their 
inhibition in the presence of DNA damage induces abnormal 
DNA replication, followed by cell death (3). For cancer treat-
ment, inhibitors of Chks are used as chemotherapeutic agents, 
in many cases with DNA damaging agents (4-6). However, 
it has been reported that Chk inhibition alone may lead to 
apoptosis in tumor cells through mutation and/or regulation of 
cellular tumor antigen p53 (p53) and cyclin-dependent kinase 
inhibitor 1 (p21) tumor suppressor genes (7). While Chk 
inhibitors may require delivery to tumor cells, they are able 
to potentially induce varying responses in other organs. The 
present study evaluated the effect of AZD7762, a Chk1 and 
Chk2 inhibitor, on three types of bone cells: Bone-resorbing 
osteoclasts, bone-forming osteoblasts, and osteocytes.
Breast cancer accounts for 25% of all cancer cases in 
women, and advanced breast cancer metastasizes to distant 
organs, most commonly bone (8). Thus, to treat breast cancer 
and protect bones from metastasis, the desired function of 
chemotherapeutic agents is the inhibition of tumor prolif-
eration and osteoclast development. It is also beneficial if the 
stimulation of osteoblast development is induced. Employing 
an inhibitor of Chk1 and Chk2, AZD7762 (362 Da), in addi-
tion to using PD407824 (328 Da) as a control Chk1 inhibitor, 
the present study examined their effects on mammary tumor 
cells, osteoclasts and osteoblasts/osteocytes. AZD7762 is a 
potent inhibitor of Chk1 and Chk2 that potentiates antitumor 
activity in xenograft models in a dose-dependent manner when 
simultaneously administered with DNA-damaging agents (9). 
PD407824 is a selective inhibitor of Chk1 (10), and its inhibi-
tory effect on tumor growth and bone resorption was recently 
reported in connection to the regulation of stress in the endo-
plasmic reticulum (ER) (11). Chk1 is a primary gatekeeper 
of cell division at multiple cell cycle checkpoints, including 
the S, G2/M and M phases. Chk2 prevents uncontrolled rapid 
cell division, and inherited mutations in Chk2 are reported to 
be associated with breast cancer (12,13). The present study 
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investigated the common effects of AZD7762 and PD407824 
as Chk1 inhibitors, in addition to the differential effects of 
Chk2 inhibition.
It was previously reported that the elevated phosphorylation 
of eukaryotic translation initiation factor-α (eIF2α) reduces the 
proliferation of tumor cells and suppresses the differentiation 
of osteoclasts (14,15). Phosphorylation of eIF2α is regulated 
by phosphatases, including protein phosphatase 1, in addition 
to four known kinases, including protein kinase RNA-like 
endoplasmic reticulum kinase (PERK). PERK is activated by 
stress in the ER (16). Using thapsigargin, an inducer of ER 
stress, the present study evaluated the role of PERK and eIF2α 
in response to AZD7762.
In the present study, the possible multiple roles of AZD7762 
in the suppression of tumor growth, inhibition of osteoclast 
development and stimulation of osteoblast development were 
investigated. Three bone cell lines were employed [RAW264.7 
pre-osteoclast cells (17), MC3T3 osteoblast-like cells (18), 
and MLO-A5 osteocyte-like cells (19)], together with 4T1.2 
mammary tumor cells. The 4T1.2 cell line was isolated from 
metastasized bone, and represents a breast cancer model of 
efficient metastasis to bone (20). The responses to AZD7762 
and PD407824 were examined in monolayer cell cultures, 
three-dimensional (3D) spheroids (21), and 3D bio-printed 
bone constructs (22). While PD407824 is able to inhibit tumor 
growth and osteoclastogenesis, its ability to promote osteoblast 
development is limited (11). It has been reported that inhibition 
of Chk2, and not Chk1, downregulates p53 expression (23). 
Since p53 is involved in osteoblast development (24), it was 
hypothesized that besides inhibitory effects on tumor cells and 
osteoclasts, AZD7762 may have more potent effects on osteo-
blastogenesis than PD407824 by a p53-dependent pathway.
Materials and methods
Cell culture. 4T1.2 mouse mammary tumor cells (obtained 
from Dr R. Anderson at Peter MacCallum Cancer Institute, 
Melbourne, Australia), MDA-MB-231 human breast cancer 
cells [American Type Culture Collection (ATCC), Manassas, 
VA, USA (25)], and MCF-7 human breast cancer cells (26) were 
cultured in Dulbecco's modified Eagle's medium (Corning 
Incorporated, Corning, NY, USA). RAW264.7 pre-osteoclast 
cells (ATCC), MC3T3 osteoblast-like cells (Sigma-Aldrich; 
Merck KGaA, Darmstadt, Germany), and MLO-A5 osteocyte-
like cells (obtained from Dr L. Bonewald at Indiana University, 
Indianapolis, IN, USA) were grown in α minimum essential 
medium (MEM; Gibco; Thermo Fisher Scientific. Inc., 
Waltham, MA, USA). Bone marrow-derived cells, obtained 
by flushing the tibia and femur from one female 10-week 
old BALB/c mouse and separating with low-density gradient 
centrifugation (27), were cultured in αMEM with 10 ng/ml 
macrophage colony-stimulating factor (PeproTech, Inc., Rocky 
Hill, NJ, USA) for 2 days, and the surface-attached cells were 
used as osteoclast precursors. The experimental procedures 
using animals were approved by the Indiana University Animal 
Care and Use Committee and were in compliance with the 
Guiding Principles in the Care and Use of Animals endorsed 
by the American Physiological Society (28). The culture media 
contained 10% fetal bovine serum (FBS; Atlanta Biologicals, 
Flowery Branch, GA, USA) and antibiotics (50 U/ml penicillin 
and 50 µg/ml streptomycin; Life Technologies; Thermo Fisher 
Scientific, Inc.). MLO-A5 cells were grown with 5% FBS and 
5% bovine calf serum. Cells were maintained at 37˚C and 5% 
CO2 in a humidified incubator, and treated with AZD7762 
(0.1-10 µM), PD407824 (0.1-20 µM), or thapsigargin (1 µM; 
Tocris Bioscience, Bristol, UK).
Cellular proliferation was evaluated using an MTT assay 
(Sigma-Aldrich; Merck KGaA), according to the manufactur-
er's protocol. The relative cell proliferation was determined as 
a ratio of the absorbance at 570 nm of each sample and control, 
as measured using a plate reader. To quantify 3D spheroid cell 
viability, the CellTiter-Glo 3D Cell Viability Assay (Promega 
Corporation, Madison, WI, USA) was used, according to the 
manufacturer's protocol, measuring luminescence with a plate 
reader.
3D spheroid assay and 3D bio-printing. To induce spheroid 
formation, ~5,000 cells were cultured in a U-bottom low-
adhesion 96-well plate (S-Bio, Hudson, NH, USA). MLO-A5 
osteocyte spheroids were bio-printed onto a needle array 
using a Regenova 3D Bioprinter (Cyfuse Biomedical K.K., 
Tokyo, Japan) (22) to generate bone constructs mineral-
ized in osteogenic medium (70 µM ascorbic acid and 5 mM 
β-glycerophosphate) (27). Each construct contained 18 osteo-
cyte spheroids (3x3x2 configuration).
Motility assay. To evaluate motility in a monolayer culture, 
a wound healing scratch motility assay was performed as 
described previously (29). In brief, cells were plated in 12-well 
plates and, the following day, scratching was performed 
using a plastic tip. The areas newly occupied with cells in the 
scratched zone were determined 24 h post-scratching using 
images obtained using a microscope (magnification, x40; 
Nikon Eclipse TS100, Nikon Corporation, Tokyo, Japan), 
which were scanned using Adobe Photoshop (CS2; Adobe 
Systems, Inc., San Jose, CA, USA) and quantified with Image 
J v1.51p (National Institutes of Health, Bethesda, MD, USA).
Osteoclast differentiation assay and pit formation assay. 
Using RAW264.7 pre-osteoclast cells, an osteoclast differ-
entiation assay was conducted in 24-well plates with 30 ng/
ml receptor activator of nuclear factor-κB ligand (RANKL) 
in the presence and absence of 0.1-2 µM AZD7762 and 
PD407824. For bone marrow-derived cells, cells were cultured 
in 10 ng/ml macrophage colony stimulating factor (M-CSF; 
Peprotech, Inc., Rocky Hill, NJ, USA) for 2 days prior to the 
addition of RANKL (27). During the 5-day experiments, the 
culture medium was replaced once on day 3. Adherent cells 
were fixed with a citrate, acetone and formaldehyde solution 
for 30 sec at room temperature and stained for 20 min at 37˚C 
with a tartrate resistant acid phosphate (TRAP)-staining kit, 
according to the manufacturer's protocol (Sigma-Aldrich; 
Merck KGaA). TRAP-positive multinucleated cells (>3 nuclei) 
were identified as mature osteoclasts (30).
A pit formation assay was conducted similarly using 24-well 
culture plates coated with hydroxyapatite (31). After 6 days, 
cells were removed with 5% sodium hypochlorite for 5 min at 
room temperature, and images of the wells were captured with 
a phase-contrast inverted microscope at x40 magnification. 
Using ImageJ, the areas of the wells no longer coated with 
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hydroxyapatite were measured, and the pit area fraction was 
calculated by normalizing to the total image area.
Alizarin red staining. MC3T3 cells were seeded on 24-well 
tissue-culture plates at 6.5x104 cells/well. Upon becoming fully 
confluent, osteogenic medium (70 µM ascorbic acid and 5 mM 
β-glycerophosphate) was added, with 0-0.5 µM AZD7762, 
and the cells were cultured for 5 weeks, changing the media 
every other day. The effect of AZD7762 on mineralization was 
evaluated by staining at room temperature for 3 min with 1% 
Alizarin Red S solution (Sigma-Aldrich; Merck KGaA) and 
imaged at x40 magnification with an inverted microscope. 
Alizarin red staining was quantified by measuring the image 
grey-scale values using ImageJ.
Reverse transcription-quantitative polymerase chain reaction 
(RT-qPCR) and RNA interference. Total RNA was extracted 
using an RNeasy Plus mini kit (Qiagen, Inc., Valencia, CA, 
USA) and RT was conducted (37˚C for 2 h; 85˚C for 5 min) 
with a high-capacity cDNA reverse transcription kit (Applied 
Biosystems; Thermo Fisher Scientific, Inc.). RT-qPCR 
was performed using Power SYBR green PCR master mix 
kits (Applied Biosystems; Thermo Fisher Scientific, Inc.) 
with the PCR primers listed in Table I. RNA interference 
was conducted using small interfering (si)RNA specific to 
PERK (cat. no. 100334), Chk1 (cat. no. 160184) and Chk2 
(cat. no. 78549; Life Technologies; Thermo Fisher Scientific, 
Inc.). A negative siRNA (Silencer Select #1; Life Technologies; 
Thermo Fisher Scientific, Inc.) was used as a nonspecific nega-
tive control. Cells were transiently transfected with siRNA 
(130 pmol per 6-cm dish) using Lipofectamine® RNAiMAX 
(Life Technologies; Thermo Fisher Scientific, Inc.) in 
Opti-MEM I medium. The medium was replaced with regular 
culture medium after 24 h, and the silencing efficiency was 
measured by immunoblotting 48 h post-transfection.
Western blot analysis. Cells were lysed in a radioimmuno-
precipitation assay buffer with protease inhibitors (Santa 
Cruz Biotechnology, Inc., Dallas, TX, USA) and phosphatase 
inhibitors (Calbiochem; Merck KGaA). Following measuring 
of the protein concentration using a Bicinchoninic Acid 
Protein Assay kit (Thermo Fisher Scientific, Inc.), ~10 µg 
isolated proteins/lane were fractionated using 10-15% 
SDS gels and electrotransferred to polyvinylidene difluo-
ride membranes (EMD Millipore, Billerica, MA, USA). 
Membranes were blocked in 2% blotting-grade blocker (Bio-
Rad Laboratories, Inc., Hercules, CA, USA) for 1 h at room 
temperature or overnight at 4˚C. Antibodies against alkaline 
phosphate (cat. no. sc-28904; Santa Cruz Biotechnology, Inc.), 
cathepsin K (cat. no. sc-48353; Santa Cruz Biotechnology, 
Inc.), PERK (cat. no. sc-13073; Santa Cruz Biotechnology, 
Inc.), nuclear factor of activated T cells cytoplasmic 1 
(NFATc1; cat. no. sc-7294; Santa Cruz Biotechnology, Inc.), 
Chk1 (cat. no. 2360; Cell Signaling Technology, Inc., Danvers, 
MA, USA), phosphorylated (p)-Chk1 (cat. no. 90178; Cell 
Signaling Technology, Inc.), Chk2 (cat. no. 2662; Cell Signaling 
Technology, Inc.), eIF2α (cat. no. 9722; Cell Signaling 
Technology, Inc.), p-eIF2α (cat. no. 9721; Cell Signaling 
Technology, Inc.), microtubule-associated proteins 1A/1B light 
chain (LC)3A/B II (cat. no. 4108; Cell Signaling Technology, 
Inc.), caspase 3 (cat. no. 9662; Cell Signaling Technology, Inc.), 
cleaved caspase 3 (cat. no. 9661; Cell Signaling Technology, 
Inc.), p38 (cat. no. 9212; Cell Signaling Technology, Inc.), 
p-p38 (cat. no. 9211; Cell Signaling Technology, Inc.), 
p-PERK (cat. no. 3179; Cell Signaling Technology, Inc.), p53 
(cat. no. MA5-12557; Invitrogen; Thermo Fisher Scientific, 
Inc.), p-Chk2 (cat. no. SAB4504366; Invitrogen; Thermo 
Fisher Scientific, Inc.), and β-actin (cat. no. A5441; Sigma-
Aldrich; Merck KGaA) were used. Primary antibodies were 
incubated for 1 h at room temperature or overnight at 4˚C 
at a 1:1,000 dilution, except Chk2, p-Chk2, p-PERK (all 
1:500), p53 (1:200) and β-actin (1:10,000), while anti-rabbit 
(cat. no. 7074; Cell Signaling Technology, Inc.) and anti-mouse 
(cat. no. 7076; Cell Signaling Technology, Inc.) secondary 
antibodies were incubated for 45 min at room temperature 
at a 1:2,000 dilution. Protein expression levels were assayed 
using a SuperSignal west femto maximum sensitivity substrate 
(Thermo Fisher Scientific, Inc.).
Fluorescence resonance energy transfer (FRET) imaging. To 
evaluate the potential role of GTPases in cellular motility, the 
activity of RhoA GTPase was determined by FRET imaging. 
In response to 2 µM AZD7762 and PD407824, energy transfer 
was measured in a RhoA-specific cyan fluorescent protein 
(CFP)-yellow fluorescent protein (YFP) biosensor (32). The 
filter sets (Semrock; IDEX Health & Science, LLC, Rochester, 
NY, USA) were chosen for CFP excitation at 438±24 nm 
(center wavelength ± bandwidth), CFP emission at 483±32 nm 
and YFP emission at 542±27 nm. Using a fluorescence micro-
scope (Nikon Corporation, Tokyo, Japan) time-lapse images 
were acquired at an interval of 5 min. The emission ratio of 
YFP/CFP for individual cells was computed to determining 
the activity levels using NIS-Elements software v3.2 (Nikon 
Corporation).
Table I. Reverse transcription-quantitative polymerase chain reaction primers used in the present study.
Target Forward primer Reverse primer
ALP 5'-CTGACTGACCCTTCGCTCTC-3' 5'-GGTCAATCCTGCCTCCTTCC-3'
OCN 5'-CCGGGAGCAGTGTGAGCTTA-3' 5'-AGGCGGTCTTCAAGCCATACT-3'
Osterix 5'-CCCTTCTCAAGCACCAATGG-3' 5'-AGGGTGGGTAGTCATTTGCATAG-3'
GAPDH 5'-TGCACCACCAACTGCTTAG-3' 5'-GGATGCAGGGATGATGTTC-3'
ALP, alkaline phosphatase; OCN, osteocalcin.
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Micro-computed tomography (CT) imaging. Micro-CT was 
performed using Skyscan 1172 (Bruker-MicroCT, Kontich, 
Belgium) (33). The printed bone constructs were wrapped in 
Parafilm to maintain hydration and placed in a plastic tube. 
Scans were performed at pixel size 6 µm. Using manufacturer-
provided software, the images were reconstructed (nRecon 
v1.6.9.18), rotated (DataViewer v1.5.0), and the bone mineral 
density of the mineralized bone construct was determined by 
calculating the mean attenuation coefficient and calibrated 
to two hydroxyapatite phantoms of known density (CTAn 
v1.11.4.2).
Statistical analysis. The data are expressed as the mean ± stan-
dard deviation of three to four replicates. One-way analysis 
of variance was employed to examine the statistical signifi-
cance among groups, and Fisher's protected least significant 
Figure 1. Inhibitory effects of AZD7762 on 4T1.2 mammary tumor cells. (A) Representative images of 4T1.2 cells in response to 1 µM AZD7762 for 24 h. 
The arrow and arrow heads indicate apoptotic and autophagic cells, respectively, assessed according to cellular morphology. (B) Relative proliferation of 
4T1.2 cells in response to 0.5, 1, 2 and 5 µM AZD7762. (C) Upregulation of p-eIF2α, and downregulation of p-Chk1 and p-Chk2. (D) Upregulation of cleaved 
caspase 3 (apoptosis marker) and LC3A/B II (autophagy marker). (E) Scratch assay and (F) wound area in response to 0.5 and 1 µM AZD7762. (G) 3D tumor 
spheroids in response to 5 and 10 µM AZD7762. (H) Cross-sectional area and (I) cell viability of 3D tumor spheroids in response to AZD7762. *P<0.05; 
**P<0.01 vs. CN. CN, control; AZD, AZD7762; 3D, three-dimensional; eIF2α, eukaryotic translation initiation factor-α; p, phosphorylated; Chk, checkpoint 
kinase inhibitor, casp, caspase; LC3A/B II, microtubule-associated proteins 1A/1B light chain 3A/B II.
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difference was conducted as a post hoc test to evaluate the 
pairwise comparisons using R 3.4.3 (R Foundation for Statistical 
Computing, Vienna, Austria). P<0.05 was considered to indicate 
a statistically significant difference.
Results
Inhibitory effects of AZD7762 on 4T1.2 mammary tumor cells. 
The present study first examined the effects of AZD7762, 
an inhibitor of Chk1 and Chk2, on the proliferation and 
migration of 4T1.2 mammary tumor cells. As the represen-
tative images of 4T1.2 cells illustrate, in response to 1 µM 
AZD7762, the cells underwent apoptosis (blebbing and cell 
shrinkage) and autophagy (increase in vacuole-like structures 
in the cytoplasm and membrane expansion), and the relative 
proliferation of the tumor cells was significantly reduced in a 
dose-dependent manner (Fig. 1A and B). Western blot analysis 
revealed that p-eIF2α was elevated in addition to cleaved 
caspase 3 (apoptosis marker) and LC3A/B II (autophagy 
marker) (Fig. 1C and D), while the expression levels of p-Chk1 
and p-Chk2 were reduced. The scratch assay for examining 
cellular motility demonstrated that the healing of the wound 
area was decreased by 0.5 and 1 µM AZD7762 (Fig. 1E 
and F), indicating that AZD7762 reduces the motility of tumor 
cells. Notably, the wound area was also enlarged as a result of 
AZD7762-driven cell death.
Since tumor growth may differ according to the culture 
conditions, the present study subsequently examined the 
effects of AZD7762 on 3D spheroids solely composed of 4T1.2 
cells (Fig. 1G). Initially, the spheroids were irregularly shaped 
with a rough surface. They gradually compacted, forming a 
necrotic core at the center and a quiescent shell around the 
core with a proliferating surface. In response to 0.5 to 10 µM 
AZD7762, the spheroids significantly altered in appearance. 
While the spheroids exhibited extended quiescent zones at the 
lower concentrations (0.5 and 1 µM AZD7762), it increased 
the necrotic core at the higher concentrations (5 and 10 µM 
AZD7762). AZD7762 reduced the cross-sectional area of 
the tumor spheroids and decreased 3D cell viability (Fig. 1H 
and I).
To evaluate its effect on other types of breast cancer, the 
present study also examined the responses of two human 
Figure 2. Inhibitory effects of AZD7762 on MDA-MB-231 and MCF-7 breast cancer cells. (A) Relative proliferation of MDA-MB-231 cells in response to 
AZD7762 on days 1-3. (B) Dose-dependent shrinkage of MDA-MB-231 tumor spheroids by AZD7762. (C) Relative proliferation of MCF-7 cells in response to 
AZD7762 on days 1-3. (D) Dose-dependent shrinkage of MCF-7 tumor spheroids by AZD7762. **P<0.01 vs. CN. CN, control; AZD, AZD7762.
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breast cancer cell lines, MDA-MB-231 and MCF-7, to 
AZD7762. MDA-MB-231 cells are estrogen receptor-negative, 
while MCF-7 cells are estrogen receptor-positive. The results 
revealed that AZD7762 inhibited the proliferation of the two 
cell lines, as measured by MTT assay, in a monolayer cell 
culture, and decreased the sizes of the 3D tumor spheroids, 
although 4T1.2 and MDA-MB-231 cells were more sensitive 
to AZD7762 compared with MCF-7 cells (Fig. 2).
Inhibitory effects of AZD7762 on RAW264.7 pre-osteoclast 
cells. Osteoclasts serve a pivotal role in bone homeostasis. 
Using RAW264.7 pre-osteoclast cells and osteoclast precursors 
from bone marrow-derived cells, the present study evaluated 
the effect of AZD7762 on the proliferation and differentiation 
of osteoclasts. Treatment with AZD7762 significantly reduced 
the proliferation of RAW264.7 cells and primary osteoclast 
precursors (Fig. 3A and B). The half-maximal inhibitory 
Figure 3. Inhibitory effects of AZD7762 on RAW264.7 pre-osteoclast cells and osteoclast precursors from bone marrow-derived cells. Relative prolif-
eration of (A) RAW264.7 cells and (B) osteoclast precursors from bone marrow-derived cells in response to 0.5 and 1 µM AZD7762 on days 1, 2 and 3, 
respectively. (C) Downregulation of NFATc1 and Cat K, and upregulation of p-eIF2α in RAW cells. (D) Upregulation of cleaved caspase 3 in RAW cells. 
(E) Downregulation of NFATc1 and upregulation of cleaved caspase 3 in osteoclast precursors from bone marrow-derived cells. (F) Visualization and (G) 
quantification of the reduction in the number of multi-nucleated TRAP-positive osteoclast cells in response to 0.5 and 1 µM AZD7762. (H) Dose-dependent 
reduction in 3D cell viability in RAW264.7 spheroids. (I) RAW264.7 spheroids in response to 0.5, 1, 5 and 10 µM AZD7762 for 24, 48 and 72 h. (J) Reduction of 
osteoclast activity by 0.5 and 1 µM AZD7762. **P<0.01 vs. CN. CN, control; AZD, AZD7762; Cat K, cathepsin K; casp, caspase; eIF2α, eukaryotic translation 
initiation factor-α; RANKL, receptor activator of nuclear factor-κB ligand; 3D, three-dimensional; NFATc1, nuclear factor of activated T cells cytoplasmic 1; 
LC3A/B II, microtubule-associated proteins 1A/1B light chain 3A/B II.
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concentration for AZD7762 in bone marrow-derived osteo-
clasts was estimated as 0.54 µM by fitting an exponential 
curve to the MTT results (data not shown). In RAW cells, 
AZD7762 also downregulated NFATc1, a master transcrip-
tion factor for osteoclastogenesis, in addition to cathepsin K, 
a marker of bone resorption (Fig. 3C). It was additionally 
observed that the expression level of p-eIF2α was elevated, 
together with cleaved caspase 3, in RAW cells (Fig. 3C and D). 
In primary osteoclast precursors, AZD7762 suppressed 
the RANKL-driven upregulation of NFATc1 and elevated 
cleaved caspase 3 expression (Fig. 3E). As demonstrated by 
TRAP staining for identifying multi-nucleated osteoclasts, 
AZD7762 significantly reduced the number of multi-nucleated 
TRAP-positive osteoclast cells in a dose-dependent manner 
(Fig. 3F and G). Furthermore, AZD7762 decreased the 3D cell 
viability of RAW264.7 spheroids in a dose-dependent manner 
(Fig. 3H). Consistent with the inhibitory effect of AZD7762 
on RAW264.7 cultured cells, AZD7762 at 0.5, 1, 5 and 10 µM 
decreased the cross-sectional area of RAW264.7 spheroids at 
24-72 h (Fig. 3I). Finally, osteoclast activity measured by a 
pit formation assay was reduced by 0.5 and 1 µM AZD7762 
(Fig. 3J).
Development of MC3T3 osteoblast-like cells in response 
to AZD7762. The present study additionally examined the 
effect of AZD7762 on osteoblast activity. AZD7762 reduced 
the relative proliferation of MC3T3 osteoblast-like cells in 
response to 0.1, 0.5, 1 and 2 µM, although the degree of reduc-
tion was smaller compared with RAW264.7 pre-osteoclast 
cells (Fig. 4A). AZD7762 increased the mRNA levels of 
osteogenesis-associated genes, including osterix, osteocalcin 
(OCN), and alkaline phosphatase (ALP) at 24 and 48 h 
(Fig. 4B and C); it also elevated the protein expression levels 
of p-eIF2α, p-p38 and ALP (Fig. 4D and E).
Comparison of the effect of AZD7762 and PD407824 on tumor 
cells. In order to evaluate any differential effects of Chk1 and 
Chk2 inhibition, PD407824, a selective inhibitor of Chk1, 
was used. The responses to PD407824 were largely similar to 
those to AZD7762. PD407824 at 0.1, 0.5 and 2 µM reduced 
Figure 4. Responses of MC3T3 osteoblast-like cells to AZD7762. (A) Relative proliferation of MC3T3 cells in response to 0.1, 0.5, 1, and 2 µM AZD7762 
on days 1, 2, and 3. Increase in the mRNA expression levels of osterix, OCN, and ALP in response to 0.1, 0.5, and 2 µM AZD7762 at (B) 24 h and (C) 48 h. 
(D) Elevation of p-eIF2α, (E) p-p38 and ALP in response to 0.1, 0.5, 1, and 2 µM AZD7762. *P<0.05; **P<0.01 vs. CN. CN, control; AZD, AZD7762; OCN, 
osteocalcin; ALP, alkaline phosphatase; p, phosphorylated; eIF2α, eukaryotic translation initiation factor-α.
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the relative proliferation of 4T1.2 cells (Fig. 5A), and the 
expression level of p-eIF2α was elevated in a dose-dependent 
manner (Fig. 5B). Furthermore, the scratch assay with 4T1.2 
mammary tumor cells revealed that PD407824 suppressed 
cell motility by inhibiting the healing of the wounded area 
(Fig. 5C). To evaluate the potential mechanism of p-eIF2α 
upregulation, the expression of p-PERK, a kinase induced 
by stress to the (ER), was evaluated. First, thapsigargin, an 
ER stress inducer, elevated p-eIF2α and p-PERK expression 
after 3 h of incubation (Fig. 5D). Second, partial silencing of 
PERK by RNA interference downregulated p-eIF2α (Fig. 5E), 
and PD407824 and AZD7762 elevated the expression level of 
p-PERK (Fig. 5F). Collectively, these data indicated that the 
elevation of p-eIF2α may be induced by p-PERK, an eIF2α 
selective kinase.
Effects of PD407824 on osteoclasts and osteoblasts. In addi-
tion to its effect on tumor cells, PD407824 affects RAW264.7 
pre-osteoclasts similarly to AZD7762. PD407824 at 0.1, 0.5 
and 2 µM reduced the relative proliferation of RAW264.7 cells 
(Fig. 5G). In MC3T3 cells, PD407824 at 0.1 and 0.5 µM did 
not significantly alter the relative cell proliferation, although a 
Figure 5. Effects of PD407824 and AZD7762 on 4T1.2 tumor cells, RAW264.7 pre-osteoclast cells and MC3T3 osteoblast-like cells. (A) Relative proliferation 
of 4T1.2 cells in response to 0.1, 0.5, and 2 µM PD407824 on day 2. (B) Upregulation of p-eIF2α by PD407824. (C) Scratch assay of 4T1.2 cells in response 
to 0.1, 0.5, and 2 µM PD407824. (D) Elevation of p-eIF2α and p-PERK by Tg. (E) Downregulation of p-eIF2α by PERK siRNA. (F) Upregulation of p-PERK 
by PD407824 and AZD7762. Relative proliferation of (G) RAW264.7 cells and (H) MC3T3 cells, respectively, in response to 0.1, 0.5, and 2 µM PD407824 
on day 2. **P<0.01 vs. CN. CN, control; AZD, AZD7762; p, phosphorylated; eIF2α, eukaryotic translation initiation factor-α; PERK, protein kinase RNA-like 
endoplasmic reticulum kinase; Tg, thapsigargin; siRNA, small interfering RNA; PD, PD407824.
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higher dosage of 2 µM decreased the number of MC3T3 cells 
(Fig. 5H). The RANKL-driven differentiation of RAW264.7 
cells was also suppressed by 0.1, 0.5 and 2 µM PD407824 in a 
dose-dependent manner (Fig. 6A and B).
Mineralization of MC3T3 and MLO-A5 cells by AZD7762. A 
major difference between AZD7762 and PD407824 was their 
effects on genes involved in bone formation. While AZD7762 
elevated the mRNA expression levels of osterix and ALP, 
PD407824 at 2 µM reduced their expression levels (Fig. 6C). 
Furthermore, the effect of PD407824 on the protein expres-
sion levels of p53, p-p38, and ALP was not notable (Fig. 6D). 
To evaluate the potential involvement of RhoA GTPase in 
the regulation of cellular motility with Chk1 inhibitors, its 
activity level was evaluated using a RhoA GTPase FRET 
biosensor. In response to 2 µM AZD7762 and PD407824, 
significant reductions in RhoA activity were observed after 
60 min (Fig. 6E).
Figure 6. Effects of PD407824 and AZD7762 on RAW264.7 pre-osteoclast cells and MC3T3 osteoblast-like cells. (A) Suppression of RANKL-driven dif-
ferentiation of RAW264.7 cells by 0.1, 0.5, and 2 µM PD407824, as demonstrated by (B) the numbers of TRAP-positive multinucleated cells. (C) Alterations in 
the mRNA expression levels of osterix, OCN and ALP by 0.1, 0.5, and 2 µM PD407824. (D) No significant alterations were observed in the protein expression 
levels of p53, p-p38 and ALP in response to 0.1 to 2 µM PD407824. (E) Reduction in RhoA activity in MC3T3 cells in response to 2 µM AZD7762 and 
PD407824. (F) Alizarin red staining of mineralized MC3T3 cells in response to 0.05, 0.1, and 0.5 µM AZD7762 for 5 weeks. (G) Dose-dependent intensity of 
alizarin red staining by AZD7762. (H) Downregulation of p53 by AZD7762. *P<0.05; **P<0.01 vs. CN. CN, control; AZD, AZD7762; PD, PD407824; OCN, 
osteocalcin; ALP, alkaline phosphatase; TRAP, tartrate resistant acid phosphate; p, phosphorylated; p53, cellular tumor antigen p53.
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The present study demonstrated that AZD7762 serves an 
inhibitory role in bone-resorbing osteoclasts. To examine its 
role in bone-forming osteoblasts, Alizarin red staining was 
performed using MC3T3 cells. The results demonstrated 
that in response to 0.05, 0.1 and 0.5 µM AZD7762 for 
5 weeks, staining intensity was elevated in a dose-dependent 
manner (Fig. 6F and G). It was also observed that AZD7762 
decreased the expression of p53 (Fig. 6H). Furthermore, 3D 
bone constructs with MLO-A5 osteocyte-like cell spheroids 
were bio-printed, and X-ray imaging was conducted after 
a 2-week incubation in osteogenic medium. The results 
revealed that bone mineral density was elevated in response 
to 0.05 and 0.1 µM AZD7762 (Fig. 7A-C). To evaluate 
the mediators of the differential effects of AZD7762 and 
PD407824 on p53 expression, partial silencing of Chk1 and 
Chk2 was conducted via siRNA in MC3T3 cells. Following 
silencing of Chk2, the AZD7762-mediated upregulation of 
ALP and downregulation of p53 were muted. However, the 
same alterations were not observed in Chk1-silenced cells 
(Fig. 7D). A proposed regulatory mechanism for AZD7762 
is illustrated in Fig. 8, in which Chk1 and Chk2 are inhib-
ited by AZD7762, as opposed to only Chk1 inhibition by 
PD407824.
Figure 7. Mineralization of MC3T3 osteoblast-like cells and MLO-A5 osteocyte-like cells by AZD7762. (A) Optical and (B) microCT-derived X-ray images 
of mineralized spheroids from MLO-A5 osteocyte-like cells in response to 0.05 and 0.1 µM AZD7762 for 2 weeks. (C) BMD of MLO-A5 spheroid constructs 
derived using microCT volumetric reconstruction. (D) Modulation of the response to PD407824 and AZD7762 by Chk1 and Chk2 siRNA in the protein 
level of ALP and p53. **P<0.01 vs. 0 µM AZD. CN, control; AZD, AZD7762; PD, PD407824; BMD, bone mineral density; CT, computed tomography; Chk, 
checkpoint kinase; siRNA, small interfering RNA; ALP, alkaline phosphatase; p53, cellular tumor antigen; NC, negative control.
Figure 8. Schematic representation of the regulatory mechanism of AZD7762 
via Chk1 and Chk2 signaling. AZD7762 and PD407824 inhibit Chk1 to sup-
press tumor proliferation and osteoclast development. AZD7762, and not 
PD407824, inhibits Chk2 to stimulate osteoblast development through p53 
signaling. Chk, checkpoint kinase; NFATc1, nuclear factor of activated T 
cells cytoplasmic 1; p-eIF2α, phosphorylated eukaryotic translation initia-
tion factor-α; p53, cellular tumor antigen p53.
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Discussion
The present study demonstrated that the Chk1 and Chk2 inhib-
itor AZD7762 suppressed tumor cell proliferation, inhibited 
osteoclast activity and stimulated osteoblast mineralization. 
Treatment with AZD7762 decreased the proliferation and 
spheroid formation of three different breast cancer cell lines 
(4T1.2, MDA-MB-231 and MCF-7). The 4T1.2 and MDA-MB-
231 cell lines are metastatic and estrogen receptor-negative, 
while MCF-7 cells are non-metastatic and estrogen receptor-
positive. Treatment with AZD7762 decreased the size and 3D 
cell viability of 4T1.2 spheroids in a dose-dependent manner. 
The inhibitory effect of AZD7762 was associated with the 
elevated protein expression of an apoptotic marker (caspase 3) 
and an autophagic marker (LC3A/BII). Of note, the role of 
autophagy is complex, and it is currently considered to func-
tion in tumor suppression and as a protective cell survival 
mechanism (34).
AZD7762 and PD407824 suppressed the 2D motility of 
4T1.2 cells in the wound healing assay, although the apparent 
reduction of motility was also due to cell death. The reduc-
tion in RhoA GTPase activity by AZD7762 and PD407824 
was consistent with their inactivation of cellular motility. The 
inhibitory effects of these two agents were evident without 
simultaneous application of DNA damaging agents. It has been 
reported that the effect of Chk inhibition on tumor growth may 
be dependent on the expression of and mutations in p53 and/or 
p21 (7). It was previously identified that inhibitors of eIF2α 
de-phosphorylation (salubrinal and guanabenz) may suppress 
tumor proliferation and osteoclast differentiation (14,15). In 
the present study, p-eIF2α was upregulated by AZD7762 and 
PD407824. Due to the observed upregulation of p-PERK, one 
possibility is that Chk1 and Chk2 inhibitors induce stress to 
the ER and elevate p-PERK and p-eIF2α expression. It is also 
possible that other kinases or phosphatases may be involved in 
the regulation of p-eIF2α.
Similar to its effects on tumor cells, AZD7762 also 
inhibited the proliferation of RAW264.7 pre-osteoclast 
cells in monolayer cultures and in 3D spheroids. Staining of 
TRAP-positive multi-nucleated osteoclasts and measuring the 
resorbed mineral area demonstrated that RANKL-induced 
osteoclast differentiation and activity was inhibited by treat-
ment with AZD7762 in a dose-dependent manner. Treatment 
with AZD7762 also decreased the protein expression of 
NFATc1, a master transcription factor of osteoclastogenesis, 
and cathepsin K, a protease involved in bone resorption, while 
increasing the phosphorylation of eIF2α and the expression 
of cleaved caspase 3. PD407824 also decreased osteoclast 
differentiation. Metastatic tumor cells that invade the bone 
may accelerate osteoclast-driven bone resorption, triggering a 
dangerous cycle (35). These results demonstrated that targeting 
Chk signaling may provide a way to slow tumor growth and 
metastasis-associated bone degradation.
While the effects of AZD7762 and PD407824 on tumor 
cells and osteoclast cells were similar, their effects on osteo-
blasts diverged. AZD7762 upregulated the mRNA expression 
levels of bone the formation markers osterix and ALP, while 
PD407824 downregulated their mRNA expression levels. 
Furthermore, AZD7762 elevated the protein expression level 
of p-p38 and reduced that of p53, and PD407824 did not 
significantly alter the levels of p-p38 or p53. RNA interference 
of Chk1 and Chk2 in osteoblasts suggested that this difference 
may have been caused by the inhibitory effect of AZD7762 on 
Chk2, thereby downregulating p53 (23), a negative regulator 
of osterix (24). Therefore, targeting Chk2 may be a way to 
attenuate bone degradation caused by metastasis. However, 
p53 is also a tumor suppressor (36), and the p53-dependent 
effects of the inhibitory effect ofAZD7762 on tumor growth 
and bone remodeling via Chk2 require further study. A 
previous study indicated the complexity of the action of p53 
as a crucial tumor suppressor, in addition to as a modulator of 
stem cell maintenance, invasion and metastasis (37).
While the present results revealed a novel role for AZD7762 
in bone remodeling and bone metastasis, the present study has 
certain limitations. The experiments herein employed mouse 
and human cell lines (11), and gene expression was primarily 
examined using monolayer cell cultures. Although clinical 
trials of AZD7762 are not going forward due to unpredictable 
cardiac toxicity, inhibition of Chk remains an important thera-
peutic target (38). Future work may aim to identify other Chk 
inhibitors that exhibit similar effects to AZD7762, and test 
their efficacy in a mouse model of bone metastasis. In conclu-
sion, the present study demonstrated that Chk1/2 inhibitors 
may be used to suppress tumor proliferation and to prevent 
bone loss via inhibition of osteoclastogenesis and stimulation 
of osteoblastogenesis.
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